Home » WebmedCentral Editors » Prashant BAVI
WebmedCentral Editor
View all WebmedCentral Editors
 
No Image

Dr. Prashant BAVI

Scientist
KIng Faisal Specialist Hospital & Research Centre
 

Brief Biography:

Prashant Bavi

M.D. Pathology, M.B.B.S

Scientist

Biological Repository Centre,

Human Cancer Genomic Research Research Centre at KFNCCC,

MBC 98-16 King Faisal Specialist Hospital & Research Centre,

P.O.Box 3354,

Riyadh 11211

Kingdom of Saudi Arabia

Phone: 966-507057910

Email: prashant.bavi@gmail.com

EDUCATION:

1999 –2001: M.D. Pathology Dayanand Medical College & Hospital, Ludhiana, Baba Farid University of Health Sciences, India.

1996 –1996: Medical Internship in Civil Hospital,  Maharashtra, India.

1991 –1995: MBBS  Dr. V.M. Medical College, Solapur, Shivaji University, Kolhapur, Maharashtra, India.

TRAINING:

2003 –2004: Senior Registrar, Pathology department, Tata Memorial Hospital, India

2002: Clinical Assistant, Dept of Lab Medicine P. D. Hinduja National Medical Hospital &  Medical Research Center, India

2002: Assistant Lecturer Grant Medical College, Sir J. J. Group of Hospitals, India

AWARDS

2003: First prize for presentation at the National Conference of Indian Academy of Pathologists & Microbiologists, India

2006, 2008 & 2010: Best research paper publication award based on impact factor awarded on the Annual Research Day at King Faisal Specialist Hospital & Research Centre,

2011: In the database of biomedical literature 'Pubget', one of my papers” Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in Colorectal Carcinoma. Am J Pathol. 2011 May;178(5):2109-20” had been ranked fourth in the 15 most read papers of the month. Most popular papers of the month are chosen based on what half a million scientists all over the world find interesting.

MEMBER OF PROFESSIONAL SOCIETIES:        

  1. American Society Of Clinical Oncology(ASCO)
  2. American Association Of Cancer Research(AACR)
  3. European Association of Cancer Research (EACR)
  4. United States & Canadian Academy OF Pathologists (USCAP)
  5. Tumor Microenvironment Working Group (TME)
  6. The American Association for the Advancement of Science(AAAS)
  7. American Society for Investigative Pathology- International Society for Biological and Environmental Repositories(ISBER)ISBER

MANUSCRIPT REVIEWER

Molecular Cancer Therapeutics

Clinical Cancer Research

Diseases Of Colon and Rectum

MANUSCRIPT- EDITORIAL BOARD

Case Reports in Pathology

EDUCATIONAL ACTIVITIES

  1. Obesity and role of leptin signaling in Saudi Tumors. Medical Grand Rounds; Dept Of Medicine, KFSHRC ; PG Auditorium, KFSHRC. 20th  December 2010
  1. Tissue Microarray For Pathologists. IHC validation and Cancer Research. ,.Presentation For Syngene International, Bristol-Myers Squibb Biocon R&D Center, Bangalore, India
  1. Tissue Microarray For Pathologists. Molecular Diagnostics For Pathologist Dept OF Pathology. KFSHRC 4-5th May 2010.
  1. Clinico-pathological significance of PIK3CA mutations in Middle Eastern Colorectal Carcinoma.  KFSH&RC Annual Research Report, KFSHRC, April 13-14, 2010
  1. King Faisal Specialist Hospital & Research Centre,  Annual Day 2008 Leptin-R is an independent prognostic factor in colorectal carcinomas.
  1. Saudi Colorectal Surgery Forum Four Seasons Hotel, Al-Mamlakah, Riyadh, Saudi Arabia, 24 to 28 March 2007, Tissue Microarray Applications in Cancer Genetics.

RESEARCH PATHOLOGIST

As a pathologist I contribute the clinical and molecular pathology part in various ongoing research projects of our department. This involves compilation of clinical data from medical charts, statistical analysis of various biomarkers and manuscript preparation. My work involves reviewing, mapping of H&E slides and tissue micro-arrays construction. Review of histopathology diagnosis including histology, tumor grading and other morphological criteria like type of tumor margin, tumor infiltrating lymphocytes, standardization of numerous research antibodies for IHC & have constructed an exhaustive IHC tissue control array. I am responsible for trouble shooting of IHC, ISH/FISH & use an automated IHC stainer (Ventana-Discovery). Quantification of biomarkers is done using digital pathology tools like Aperio Scanscope and Tissue Mine software with optimal cutpoint of biomarkers being ascertained by use of bioinformatics tool X-Tile.  I am also responsible for the collection of fresh tumor tissue samples from Pathology & their proper storage in our tissue bank using Freezerworks software. Subsequently, I validate the representativeness of the tissue samples stored in the freezers of the Tissue Bank by means of laser microdissection using Arcturus LMD microscope on frozen section technique. I am versatile in all forms of medical writing –grant writing, research proposals, press releases, meeting abstracts and manuscripts.

All in all, I am responsible for establishing a supply of high quality cancer biospecimens; setup workflow to ensure robust validation and maximal reproducibility; participate actively in study design, planning and execution with my colleagues.

ADMINISTRATIVE

I train the technical staff to ensure high standards. I am responsible for budgeting, allocation of funding and independently order all lab equipment. I do an annual valuation of 6-8 technical staff including one Assistant Pathologist. I am also responsible for identifying potential new candidates, placing job advertisements, conducting interviews and hiring staff.

MAJOR RESEARCH AREAS

  1. Oncopathology, biomarker discovery and personalized medicine
  2. Bio-banking
  3. Molecular Pathology: refinements in tissue microarrays, IHC and in situ hybridizations.
 

Academic positions:

Scientist at King Faisal Specialist Hospital & Research Centre
Past
Postdoctoral fellow at King Faisal Specialist Hospital
Senior registrar at Tata Memorial Hospital
Clinical Assistant Dept of Lab Medicine at P. D. Hinduja National Medical Hospital & Medical Research Center, Mumbai, India
Assistant Lecturer at Grant Medical College, Sir J. J. Group of Hospitals, Mumbai, India
MD student at Dayanand Medical College & Hospital, Ludhiana, IndiaObserver at Tata Memorial Hospital, Mumbai, India
MBBS student at Dr V.M. Medical College & Hospital

 

Research interests:

Oncology,  Biomarkers, Anatomic Pathology,  molecular pathology,  biobanking,  tissue microarray, Digital Pathology,  Immunohistochemistry,  Personalized Medicine, Translational Research,  theranostics,  statistical analysis,  Scientific Writing, Clinical Data Management,  University Teaching,  lateral thinking and  Mind mapping.

 

Any other information:

I am a pathologist with a rich and diverse experience in oncopathology, biobanking, digital pathology, translational research and lab administration. I am currently working at King Faisal Specialist Hospital & Research Centre, Riyadh in translational cancer research and head a biorepository section. I am actively involved in designing projects in collaboration with clinicians, and many a times act as a link between clinicians and my research colleagues who do not have the clinical background or perspective. A measure of the success of the research program and the team of which I am a valuable member, is reflected in our/my track record of over 50 publications in high impact peer reviewed journals and more than 70 presentations in international meetings. My other skills include competence in all aspects of scientific writing including reviewing manuscripts, data management and statistical analysis. Harvesting the best quality samples, meaningful biomarker discovery and making an impact on personalized medicine are my future goals. A rich, diverse experience in pathology and in cancer research, additional productivity traits of being a proponent of lateral thinking, active mind map user, learning an attitude to question dogma are some of my inherent strengths. An avid Mac user, I firmly believe in Steve Jobs’s philosophy -“Stay hungry stay foolish”. It is my conviction that I can relate to the “DNA” of Webmedcentral culture that has the foundations of a scientific, data-driven mindset, strong patient focus and an environment of "casual intensity." My passion, zeal in pathology and a rich experience translational research experience  makes me feel that I can make valuable contributions to the editorial team of webmedcentral plus. I look forward to your reply. Thank you

PUBLICATIONS:
1. Bu R, Uddin S, Ahmed M, Hussain AR, Alsobhi S, Amin T, Al-Nuaim A, Al-Dayel F, Abubaker J, Bavi P, Al-Kuraya KS. c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce Papillary Thyroid Carcinoma cell death. Mol Med. 2011 Nov 16. doi: 10.2119/molmed.2011.00238. [Epub ahead of print]
2. Uddin S, Hussain AR, Siraj AK, Khan OS, Bavi PP, Al-Kuraya KS. Role of leptin and its receptors in the pathogenesis of thyroid cancer. Int J Clin Exp Pathol. 2011;4(7):637-43. Epub 2011 Oct 3.
3. Al Tassan N, Khalil D, Shinwari J, Al Sharif L, Bavi P, Arifeen Z, Dhaim NA,Magrashi A, Bobis S, Ahmed H, Alahmed S, Bohlega S. A Missense Mutation in PIK3R5 Gene in a Family with Ataxia and Oculomotor Apraxia. Hum Mutat. 2011 Nov 7. doi: 10.1002/humu.21650. [Epub ahead of print]
4. Ahmed M, Uddin S, Hussain AR, Alyan A, Jehan Z, Al-Dayel F, Al-Nuaim A, Al-Sobhi S, Amin T, Bavi P, Al-Kuraya KS. FoxM1 and Its Association with Matrix Metalloproteinases (MMP) Signaling Pathway in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2011 Nov 2. [Epub ahead of print] PubMed PMID: 22049175.
5. Bavi P, Bu R, Uddin S, Al-Kuraya KS. MMP7 Polymorphisms - A new tool in molecular pathology to understand esophageal cancer. Saudi J Gastroenterology 2011:17(5);299-300. [EDITORIAL]
6. Uddin S, Hussain AR, Ahmed M, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. Coexpression of Activated c-Met and Death Receptor 5 Predicts Better Survival in Colorectal Carcinoma. Am J Pathol. 2011Oct 3. [Epub ahead of print]
7. Bavi P,Abubaker J, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Uddin S, Siraj A, Al-Kuraya K. Clinico-pathological significance of TNF alpha-induced protein3 (TNFAIP3) in Middle Eastern colorectal carcinoma Clinical Epigenetics 2011 Aug 01 Volume 2, Number 2, 417-418, DOI: 10.1007/s13148-011-0049-z
8. Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R, Abubaker J, Sultana M, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Prabhakaran S, Hussain AR, Al-Kuraya KS. Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in Colorectal Carcinoma. Am J Pathol. 2011 May;178(5):2109-20.
9. Bavi P, Uddin S, Bu R , Ahmed M, Abubaker J, Balde V, Qadri Z, Ajarim D, Al-Dayel F, Prabhakaran S, Hussain AR, Al-Kuraya KS. The biological and clinical impact of inhibition of NF- B initiated apoptosis in diffuse large B-cell lymphoma (DLBCL). J Pathol. 2011 Feb 3. doi: 10.1002/path.2864. [Epub ahead of print]
10. Uddin S, Jehan Z, Ahmed M, Alyan A, Al-Dayel F, Hussain A, Bavi P, Al-Kuraya KS. Over Expression of Fatty Acid Synthase in Middle Eastern Epithelial Ovarian Carcinoma Activates AKT and its Inhibition Potentiates Cisplatin Induced Apoptosis. Mol Med. 2011 Mar 21. doi: 10.2119/molmed.2011.00046.
11. Uddin S, Ahmed M, Hussain AR, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari L, Alhomoud S, Al-Dayel F, Jehan Z, Bavi P, Siraj AK, Al-Kuraya KS. Genome Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy. Am J Pathol. 2011 – IN PRESS
12. Siraj AK, Hussain AR, Al-Rasheed M, Ahmed M, Bavi P, Alsobhi S, Alnuaim A, Uddin S, Al-Kuraya K. Demethylation of TMS1 Gene Sensitizes Thyroid Cancer Cells to TRAIL-Induced Apoptosis. J Clin Endocrinol Metab. 2011 Jan;96(1):E215-24.
13. Bu R, Uddin S, Bavi P, Hussain AR, Al-Dayel F, Ghourab S, Ahmed M, Al-Kuraya K. HGF/c-Met pathway plays a prominent role in mediating antiapoptic signals via AKT in epithelial ovarian carcinoma. Lab Invest. 2011 Jan;91(1):124-37. Epub 2010 Jul 26.
14. Bavi P, Prabhakaran SE, Abubaker J, Qadri Z, George T, Al-Sanea N, AbduljabbarA, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Uddin S, Al-Kuraya KS.Prognostic significance of TRAIL death receptors in Middle Eastern colorectalcarcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer. 2010 Jul 30;9:203.
15. Uddin S, Hussain AR, Ahmed M, Al-Dayel F, Bu R, Bavi P, Al-Kuraya KS. Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. Lab Invest. 2010 Jun 7. [In press]
16. Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol. 2010 Oct;222(2):180-90.
17. Uddin S, Bu R, Ahmed M, Hussain AR, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. Leuk Lymphoma. 2010 Jul;51(7):1305-14.
18. Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS. Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Mol Cancer Ther. 2010 May;9(5):1244-55.
19. Uddin S, Bavi P, Siraj AK, Ahmed M, Al-Rasheed M, Hussain AR, Ahmed M, Amin T, Alzahrani A, Al-Dayel F, Abubaker J, Bu R, Al-Kuraya KS. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma. Endocr Relat Cancer. 2010 Feb 18;17(1):191-202. Print 2010 Mar. {Joint first author}
20. Morales J, Al-Sharif L, Khalil DS, Shinwari JM, Bavi P, Al-Mahrouqi RA, Al-Rajhi A, Alkuraya FS, Meyer BF, Al Tassan N. Homozygous mutations in ADAMTS10 and ADAMTS17 cause lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short stature. Am J Hum Genet. 2009 Nov;85(5):558-68.
21. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol. 2009 Dec;219(4):435-45. {Joint first author}
22. Uddin S, Bu R, Ahmed M, Abubaker J, Al-Dayel F, Bavi P, Al-Kuraya KS. Overexpression of leptin receptor predicts an unfavorable outcome in Middle Eastern ovarian cancer. Mol Cancer. 2009 Sep 18;8:74
23. Alazami AM, Shaheen R, Alzahrani F, Snape K, Saggar A, Brinkmann B, Bavi P, Al-Gazali LI, Alkuraya FS. FREM1 mutations cause bifid nose, renal agenesis, and anorectal malformations syndrome. Am J Hum Genet. 2009 Sep;85(3):414-8. Erratum in: Am J Hum Genet. 2009 Nov;85(5):756.
24. Jehan Z, Bavi P, Sultana M, Abubaker J, Bu R, Hussain A, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol. 2009 Nov;219(3):337-46.{Joint first author}
25. Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS. PIK3CA alterations in Middle Eastern ovarian cancers. Mol Cancer. 2009 Jul 28;8:51.
26. Uddin S, Ahmed M, Hussain AR, Jehan Z, Al-Dayel F, Munkarah A, Bavi P, Al-Kuraya KS. Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer. Lab Invest. 2009 Oct;89(10):1115-27.
27. Uddin S, Ahmed M, Hussain A, Assad L, Al-Dayel F, Bavi P, Al-Kuraya KS, Munkarah A. Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer. Int J Cancer. 2010 Jan 15;126(2):382-94.
28. Uddin S, Bavi PP, Hussain AR, Alsbeih G, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Ahmed M, Al-Kuraya KS. Leptin receptor expression in Middle Eastern colorectal cancer and its potential clinical implication. Carcinogenesis. 2009 Nov;30(11):1832-40. {Joint first author}
29. Uddin S, Hussain AR, Ahmed M, Abubaker J, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Bavi P, Al-Kuraya KS. High prevalence of fatty acidsynthase expression in colorectal cancers in Middle Eastern patients and itspotential role as a therapeutic target. Am J Gastroenterol. 2009 Jul;104(7):1790-801.
30. Alazami AM, Al-Saif A, Al-Semari A, Bohlega S, Zlitni S, Alzahrani F, Bavi P, Kaya N, Colak D, Khalak H, Baltus A, Peterlin B, Danda S, Bhatia KP, SchneiderSA, Sakati N, Walsh CA, Al-Mohanna F, Meyer B, Alkuraya FS. Mutations in C2orf37,encoding a nucleolar protein, cause hypogonadism, alopecia, diabetes mellitus,mental retardation, and extrapyramidal syndrome. Am J Hum Genet. 2008 Dec;83(6):684-91.
31. Uddin S, Hussain A, Ahmed M, Belgaumi A, Al-Dayel F, Ajarim D, Bavi P,Al-Kuraya KS. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. J Pathol. 2008 Dec;216(4):483-94.
32. Jehan Z, Siraj AK, Abubaker J, Ruiz C, Simon R, Sultana M, Uddin S, Bavi P,Hussain A, Razack S, Ezzat A, Al-Dayel F, Sauter G, Al-Kuraya KS. Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma.Oncology. 2008;75(1-2):71-80.
33. Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A,Al-Sobhi S, Al-Dayel F, Bavi P, Hussain AR, Al-Kuraya KS. Fatty acid synthase andAKT pathway signaling in a subset of papillary thyroid cancers. J Clin EndocrinolMetab. 2008 Oct;93(10):4088-97.
34. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH,Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS. Bortezomib (Velcade) inducesp27Kip1 expression through S-phase kinase protein 2 degradation in colorectalcancer. Cancer Res. 2008 May 1;68(9):3379-88.
35. Bavi P, Abubaker J, Hussain A, Sultana M, Al-Dayel F, Uddin S, Al-Kuraya KS. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol. 2008 Jun;39(6):885-94.
36. Al-Dayel F, Al-Rasheed M, Ibrahim M, Bu R, Bavi P, Abubaker J, Al-Jomah N,Mohamed GH, Moorji A, Uddin S, Siraj AK, Al-Kuraya K. Polymorphisms ofdrug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. LeukLymphoma. 2008 Jan;49(1):122-9.
37. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Uddin S, Al-Kuraya KS. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Easternpopulation. Oncogene. 2008 Jun 5;27(25):3539-45. {Joint first author}
38. Bavi PP, Abubaker JA, Jehan ZD, Al-Jomah NA, Siraj AK, Al-Harbi SR, AtizadoVL, Abduljabbar AS, Alhomoud SJ, Ashari LH, Al-Dayel FH, Uddin S, Al-Kuraya KS,Alsanea NA. Colorectal carcinomas from Middle East. Molecular and tissuemicroarray analysis of genomic instability pathways. Saudi Med J. 2008Jan;29(1):75-80.
39. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A,Ahmed M, Amin T, Al-Fehaily M, Al-Sanea O, Al-Dayel F, Uddin S, Al-Kuraya KS.Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab. 2008 Feb;93(2):611-8.
40. Siraj AK, Ibrahim M, Al-Rasheed M, Bu R, Bavi P, Jehan Z, Abubaker J, MuradW, Al-Dayel F, Ezzat A, El-Solh H, Uddin S, Al-Kuraya K. Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. Ann Hematol. 2007Dec;86(12):887-95.
41. Siraj AK, Bavi P, Abubaker J, Jehan Z, Sultana M, Al-Dayel F, Al-Nuaim A,Alzahrani A, Ahmed M, Al-Sanea O, Uddin S, Al-Kuraya KS. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J Pathol. 2007 Oct;213(2):190-9.
42. Bavi P, Jehan Z, Atizado V, Al-Dossari H, Al-Dayel F, Tulbah A, Amr SS,Sheikh SS, Ezzat A, El-Solh H, Uddin S, Al-Kuraya K. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1708-18.
43. Abubaker J, Bavi PP, Al-Harbi S, Siraj AK, Al-Dayel F, Uddin S, Al-Kuraya K. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma. Leukemia. 2007 Nov;21(11):2368-70.
44. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, AtizadoV, Al-Dayel F, Belgaumi A, El-Solh H, Ezzat A, Bavi P, Al-Kuraya KS. Role ofphosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 2006 Dec 15;108(13):4178-86.
45. Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA,Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G,Terracciano L, Tornillo L. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007 Jul;60(7):768-72
46. Al Kuraya K, Siraj AK, Bavi P, Al-Jomah N, El-Solh H, Ezzat A, Al-Dayel F,Belgaumi A, Al-Kofide A, Sabbah R, Sheikh S, Amr S, Simon R, Sauter G. Highthroughput tissue microarray analysis of FHIT expression in diffuse large cellB-cell lymphoma from Saudi Arabia. Mod Pathol. 2006 Aug;19(8):1124-9.
47. Al-Kuraya K, Narayanappa R, Al-Dayel F, El-Solh H, Ezzat A, Ismail H,Belgaumi A, Bavi P, Atizado V, Sauter G, Simon R. Epstein-Barr virus infection isnot the sole cause of high prevalence for Hodgkin's lymphoma in Saudi Arabia. Leuk Lymphoma. 2006 Apr;47(4):707-13.
48. Al-Kuraya K, Siraj AK, Bavi P, Al-Jommah N, Ezzat A, Sheikh S, Amr S,Al-Dayel F, Simon R, Guido S. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. HumPathol. 2006 Apr;37(4):453-7.
49. Al-Kuraya KS, Bavi PP, Ezzat AA, Al-Dayel FA, Uddin S, Atizado VL, Al-Jomah NA, Amr SS, Sheikh SS, Sauter G, Simon R. Colorectal carcinoma from Saudi Arabia.Analysis of MLH-1, MSH-2 and p53 genes by immunohistochemistry and tissue microarray analysis. Saudi Med J. 2006 Mar;27(3):323-8.
50. Bavi P, Shet T, Gujral S. Malignant melanoma of mediastinum misdiagnosed as a spindle cell thymoma in a fine needle aspirate: a case report. Acta Cytol. 2005 Jul-Aug;49(4):424-6.

 

What I think of the idea behind WebmedCentral:

It is a great idea but still evolving and needs to be nurtured to realize its full potential. Peer review is but an imperfect method and even if we find a lesser evil to this methodology it would be a great start.

 
 
We use cookies on this website to measure and improve performance. By continuing to browse the site, you are agreeing to our use of cookies.